N. Bouchkouj

A Pan-Inhibitor of DASH Family Enzymes Induces Immune-mediated Regression of Murine Sarcoma and Is a Potent Adjuvant to Dendritic Cell Vaccination and Adoptive T-cell Therapy

T. Fry, C. Mackall, J. Lai, 2013, Journal of immunotherapy.

Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

A. Baruchel, Abraham I. Bassan, G. Vassal, 2021, European journal of cancer.

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma

Amy McKee, R. Pazdur, B. George, 2018, Clinical Cancer Research.

FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.

Zhenzhen Xu, M. Theoret, D. Przepiorka, 2022, The oncologist.

Outreach to Immigrant Communities: Teaching Pediatric Residents about Access to Health Care

D. Feldman, N. Bouchkouj, R. Karp, 2007, Journal of health care for the poor and underserved.

Patient Reported Outcomes in Pediatric Cancer Registration Trials: A U.S. Food and Drug Administration Perspective.

B. King-Kallimanis, G. Reaman, P. Kluetz, 2021, Journal of the National Cancer Institute.